Linker Information
General Information of This Linker
| Linker ID |
LIN0SXNVZ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Vali-Ala dipeptide linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
SC-002 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
14.29%
|
|||
| Patients Enrolled |
Small-cell lung cancer (either limited or extensive disease) or large cell neuroendocrine carcinoma that had relapsed or was refractory to treatment following 1 prior systemic chemotherapy and for which no curative therapy was available were eligible for the phase 1a dose-escalation.
|
||||
| Administration Dosage |
7 dose levels (0.025-0.40 mg/kg), 3+3 design.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02500914 | Clinical Status | Phase 1a/1b | ||
| Clinical Description |
A phase 1a/1b dose escalation and expansion study of single-agent SC-002 in subjects with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma.
|
||||
| Primary Endpoint |
All patients (N = 35) were included in response analyses. Five patients (14.29%) overall achieved a PR per investigator assessment,with no patients achieving a CR. One patient each had a PR in the 0.20 and 0.30 mg/kg Q3W dose groups, and 3 patients in the 0.40 mg/kg Q9W dose group, fourteen (40.00%) patients achieved stable disease as their best overall response,and 5 had no or an non-evaluable posttreatment scan.
Click to Show/Hide
|
||||
| Other Endpoint |
Nineteen patients had tumor samples that were able to be assessed for DLL3 expression by immunohistochemistry. DLL3-positive expression by immunohistochemistry (DLL3 >0%) was confirmed in 17 patients; 5 were DLL3 high (75.00% DLL3 positive cells). Of DLL3-positive patients, 2 (11.80%) achieved a PR, including 1 patient in the 0.20 mg/kg Q3W cohort and 1 DLL3-high patient in the 0.40 mg/kg Q9W cohort.
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02500914 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1a/1b dose escalation and expansion study of single-agent SC-002 in subjects with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma.
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.